TAVR Linked to Higher Reintervention Rate than SAVR in Evolut Low Risk Trial Update

Why It Matters

The emerging durability gap could shift treatment algorithms for low‑risk aortic stenosis and spur redesign of transcatheter valves and procedural protocols.

Key Takeaways

• Six‑year TAVR reintervention 5.5%, SAVR 3.3%.
• Seven‑year gap widens: TAVR 9.8%, SAVR 6%.
• Aortic regurgitation drives most TAVR reinterventions.
• Off‑guidance post‑dilation increases regurgitation risk.
• Mortality and stroke remain statistically similar.

Pulse Analysis

The Evolut Low Risk trial has been a benchmark for expanding transcatheter aortic valve replacement (TAVR) into younger, low‑risk cohorts. While early results demonstrated parity with surgical aortic valve replacement (SAVR) on mortality and stroke, the six‑year follow‑up now reveals a divergence in durability, with TAVR patients experiencing noticeably more repeat interventions. This trend aligns with broader industry concerns that the rapid adoption of TAVR may outpace long‑term performance data, prompting regulators and manufacturers to prioritize durability metrics alongside acute outcomes.

A deeper dive into the reintervention data points to aortic regurgitation (AR) as the primary driver. Patients receiving the Evolut R platform exhibited higher AR rates than those with the Evolut PRO, and off‑guidance post‑dilation amplified the risk. These procedural nuances suggest that device selection and adherence to manufacturer‑specified deployment techniques are critical levers for mitigating late valve dysfunction. Moreover, the similarity in reintervention rates for aortic stenosis itself indicates that structural valve degeneration is not the sole culprit; hemodynamic inefficiencies introduced during implantation play a substantial role.

For clinicians, the findings reinforce the importance of heart‑team deliberations that weigh immediate procedural benefits against potential long‑term trade‑offs. Ongoing surveillance programs and standardized definitions of bioprosthetic valve dysfunction will be essential to identify patients at risk early. Meanwhile, manufacturers are likely to accelerate refinements in valve design—such as enhanced sealing skirts and adaptive frame technologies—to curb AR and improve durability, ensuring TAVR remains a competitive option for low‑risk patients over the next decade.